| Chronic Obstructive Airway Disease
Nucala vs Trelegy Ellipta
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Nucala vs Trelegy Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Nucala based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Nucala, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nucala
Trelegy Ellipta
At A Glance
SC injection
Every 4 weeks
IL-5 antagonist
Oral inhalation
Once daily
ICS/LAMA/LABA
Indications
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Contraindications
- History of hypersensitivity to mepolizumab or excipients in the formulation
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Pharmacology
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Trelegy Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NucalaView full Nucala profile
Trelegy ElliptaView full Trelegy Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.